Polytetrafluoroethylene
Skin Exposure Reduction Paste Against Chemical Warfare Agents (polytetrafluoroethylene) is a small molecule pharmaceutical. Polytetrafluoroethylene was first approved as Skin exposure reduction paste against chemical warfare agents on 2000-02-17.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Perfluoropolymethylisopropyl ether
+
Polytetrafluoroethylene
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS | US ARMY MED RES | N-021084 DISCN | 2000-02-17 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
113 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tooth loss | D016388 | — | — | — | 1 | 1 | 1 | 1 | 3 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | 1 | 1 | 2 |
| Hernia | D006547 | HP_0100790 | K40-K46 | — | — | — | 1 | 1 | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | — | 1 |
| Dehydration | D003681 | — | E86.0 | — | — | — | 1 | — | 1 |
| Peripheral catheterization | D002406 | — | — | — | — | — | 1 | — | 1 |
| Ventral hernia | D006555 | EFO_1001866 | K43 | — | — | — | 1 | — | 1 |
| Recurrence | D012008 | — | — | — | — | — | 1 | — | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | 1 | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alveolar bone loss | D016301 | — | — | — | 2 | 1 | — | 2 | 4 |
| Hiatal hernia | D006551 | EFO_0007216 | K44 | — | — | 1 | — | 1 | 2 |
| Peri-implantitis | D057873 | EFO_1001390 | — | — | — | 1 | — | 1 | 2 |
| Peripheral nerve injuries | D059348 | — | — | — | 1 | 1 | — | — | 1 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | 1 | — | — | 1 |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 2 | — | — | 2 | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 1 | 2 |
| Telangiectasis | D013684 | — | — | — | 1 | — | — | — | 1 |
| Radiation injuries | D011832 | — | T66 | — | 1 | — | — | — | 1 |
| Malignant pleural effusion | D016066 | — | J91.0 | 1 | 1 | — | — | — | 1 |
| Tissue adhesions | D000267 | — | — | — | 1 | — | — | — | 1 |
| Vocal cord paralysis | D014826 | HP_0001605 | J38.0 | — | 1 | — | — | — | 1 |
| Anatomical pathological conditions | D020763 | — | — | — | 1 | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Soft tissue injuries | D017695 | — | — | 1 | — | — | — | 1 | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 3 | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 3 | 3 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 3 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 2 | 2 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 2 | 2 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | — | — | 2 | 2 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | — | 2 | 2 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 2 | 2 |
Show 45 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Polytetrafluoroethylene |
| INN | politef |
| Description | Polytetrafluoroethylene (PTFE) is a synthetic fluoropolymer of tetrafluoroethylene. It belongs to the per- and polyfluoroalkyl substances (PFAS)) and has numerous applications. The commonly known brand name of PTFE-based composition is Teflon by Chemours, a spin-off from DuPont, which originally discovered the compound in 1938.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9002-84-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201480 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | E1NC1JVS3O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,739 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use